MD Anderson and Summit Therapeutics partner to accelerate ivonescimab development

BOSTON — A mathematical model predicts that the prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) — formerly known as nonalcoholic fatty liver disease (NAFLD)

Break­through Prop­er­ties is back keep­ing the dirt fly­ing in biotech — this time break­ing new ground in Am­s­ter­dam. The com­mer­cial re­al es­tate al­liance be­tween Tish­man